An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study (CD02_EA)
Primary Purpose
HIV
Status
No longer available
Phase
Locations
United States
Study Type
Expanded Access
Intervention
PRO 140
Sponsored by

About this trial
This is an expanded access trial for HIV
Eligibility Criteria
This study will recruit one treatment-experienced, HIV-1 infected patient with CCR5-tropic virus, who has participated in PRO 140_CD02 clinical trial and is continuing to derive clinical benefit from PRO 140 treatment.
Sites / Locations
- CD02 EA Investigational site
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT02759042
First Posted
April 19, 2016
Last Updated
March 12, 2018
Sponsor
CytoDyn, Inc.
Collaborators
Amarex Clinical Research
1. Study Identification
Unique Protocol Identification Number
NCT02759042
Brief Title
An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
Acronym
CD02_EA
Official Title
An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study
Study Type
Expanded Access
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CytoDyn, Inc.
Collaborators
Amarex Clinical Research
4. Oversight
5. Study Description
Brief Summary
The primary objective is to provide continued access to PRO 140 to a subject who has completed participation in PRO140_CD02.
Detailed Description
This is an open label, single center study designed to provide continued access to PRO 140 to a subject who have completed participation in PRO140_CD02 and continue to receive clinical benefit.
The subject will receive weekly PRO 140 SC injection along with oral ART regimen during the Treatment Phase. The study treatment (PRO 140 SC injections) will be administered by a qualified medical professional or self-administered by the subject.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
PRO 140
Other Intervention Name(s)
PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5
Intervention Description
PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
56 Years
Eligibility Criteria
This study will recruit one treatment-experienced, HIV-1 infected patient with CCR5-tropic virus, who has participated in PRO 140_CD02 clinical trial and is continuing to derive clinical benefit from PRO 140 treatment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Edwin DeJesus, MD, FIDSA
Organizational Affiliation
Orlando Immunology Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
CD02 EA Investigational site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
12. IPD Sharing Statement
Learn more about this trial
An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
We'll reach out to this number within 24 hrs